RE:ONCY's GOBLET trial's pancreatic cohort exceeds expectationsAs background - Pandy et al (2019) found that high CEACAM6 expression is associated with low cytolytic T-cell activity in both basal and classical PDA subtypes and correlates with low levels of T-REG markers. The authors also found that CEACAM6, a key regulator affects several hallmarks of PDA including the fibrotic reaction, immune regulation, energy metabolism and is a novel therapeutic target in PDA. which supports the benefit of the use CEACAM5 as a biomarker in diagnosing pancreatic cancer and the use of pelareorep + immune checkpoint inhibitors as an IO treatment for this cancer.
https://pubmed.ncbi.nlm.nih.gov/31797958/
In addition, this positive result points to the potential use of pelareorep + immune checkpoint inhibitors with anti-CD47 agents, known to block the "don't eat me" gene that Pfizer recently acquired through the US$2.3 Billion purchase of Trillium Therapeutics in the treatment of pancreatic cancer and other solid tumors.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-trillium-therapeutics-inc